Zimbabwe has rejected a major US health deal worth $367m (272 million pounds) spanning five years because of Washington's request for sensitive data.
This move was revealed following a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesman has since stated that the United States was demanding access to biological samples for research and commercial gain while refused to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more talks to find a agreement acceptable to both sides so the nation's critical HIV programme can be sustained.
Broader Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were raised about the safety of citizens' health data.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and accountability.
Based on reports, 16 African countries have to date signed similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery with no assurance that the end products would be accessible to our population if a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were undermining structures already set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration could be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it understood the government's concerns, but suggested that talks should continue considering much of the nation's HIV programmes depended on international support.
"If specific concerns arise, such as those involving information security or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," the group said.
The situation highlights the ongoing debate between receiving vital international aid and safeguarding national sovereignty in an ever more data-driven world.